Cargando…
Safety of liposome extended-release bupivacaine for postoperative pain control
Background: Ideal postoperative pain management requires a multidisciplinary approach in combination with a variety of dosage regimens. Approximately 21–30% of patients experience moderate to severe pain in the postoperative period, which may have a significant impact on recovery rate, standard of l...
Autores principales: | Portillo, Juan, Kamar, Nawal, Melibary, Somayah, Quevedo, Eduardo, Bergese, Sergio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012190/ https://www.ncbi.nlm.nih.gov/pubmed/24817851 http://dx.doi.org/10.3389/fphar.2014.00090 |
Ejemplares similares
-
Liposomal extended-release bupivacaine for postsurgical analgesia
por: Lambrechts, Mark, et al.
Publicado: (2013) -
Efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia
por: Bergese, Sergio D, et al.
Publicado: (2012) -
Abstract: Liposome Bupivacaine for Postoperative Pain Control for Labiaplasty
por: Fukuzawa, Minako, et al.
Publicado: (2018) -
Retrospective analysis of quality improvement when using liposome bupivacaine for postoperative pain control
por: King, Nicole M, et al.
Publicado: (2016) -
Tacrolimus Intrapatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation
por: Del Bello, Arnaud, et al.
Publicado: (2021)